From Spheroids to Tumor-on-a-Chip for Cancer Modeling and Therapeutic Testing

Area of Science:

• Oncology
• Biomedical Engineering
• Drug Discovery

Background:

• High failure rates of anticancer drugs in clinical trials necessitate improved preclinical models.
• Conventional 2D cultures and animal models lack the complexity to predict clinical outcomes.
• Three-dimensional (3D) systems are being developed to better emulate the human tumor microenvironment.

Purpose of the Study:

• To review recent advances in microfluidic spheroid models for cancer research.
• To highlight the potential of these models in improving preclinical drug testing.
• To discuss device design, biomaterial integration, and translational validation of these systems.

Main Methods:

• Integration of 3D spheroids with microfluidic technology.
• Precise control of microenvironmental factors (nutrients, oxygen, shear stress, pressure).
• Co-culture capabilities with stromal, immune, and endothelial cells.

Main Results:

• Microfluidic spheroid models enable investigation of drug response, angiogenesis, metastasis, and immune interactions.
• These platforms offer dynamic and physiologically relevant conditions for cancer research.
• Recent advances cover device design, biomaterials, and translational validation for carcinomas and sarcomas.

Conclusions:

• Microfluidic spheroid technology offers a promising pathway for predictive, ethical, and personalized preclinical cancer testing.
• These models bridge the gap between in vitro studies and clinical oncology.
• Challenges include technical complexity, scalability, and standardization, which require further attention.